Content about Personalized medicine

December 13, 2013

A recent study commissioned by Intel revealed that patients are ready to embrace personalized care, all the way down to medications for their specific genetic makeup, and they want the freedom to get health care wherever and whenever it’s convenient for them.

Why is this important? Personalization — whether it is customized coupons and marketing or prescription medications — is here and will be critical in 2014. Consumers want more, and in the face of rising healthcare costs and a strained health care system, their healthcare is no exception.

A recent study commissioned by Intel revealed that patients are ready to embrace personalized care, all the way down to medications for their specific genetic makeup, and they want the freedom to get health care wherever and whenever it’s convenient for them.

December 10, 2013

Personalized medicine is on the horizon, and patients are not only awaiting it optimistically, but they also are willing to share a bit of personal information when it comes, according to a new study released Monday commissioned by Intel.

SANTA CLARA, Calif. — Personalized medicine is on the horizon, and patients are not only awaiting it optimistically, but they also are willing to share a bit of personal information when it comes, according to a new study released Monday commissioned by Intel. 

October 31, 2013

Earlier this year, the Food and Drug Administration approved a new drug for treating cystic fibrosis for patients who have a specific genetic mutation, but that also treats the underlying cause of the disease rather than the disease itself.

SILVER SPRINGS, Md. — Earlier this year, the Food and Drug Administration approved a new drug for treating cystic fibrosis for patients who have a specific genetic mutation, but that also treats the underlying cause of the disease rather than the disease itself.

October 31, 2013

A personalized medicine company said a new study justifies clinical use of pharmacogenomic testing to help predict patients' response to psychiatric medications and improve treatment outcomes.

MASON, Ohio — A personalized medicine company said a new study justifies clinical use of pharmacogenomic testing to help predict patients' response to psychiatric medications and improve treatment outcomes.

March 26, 2013

It’s often the case that those in the midst of revolutionary times don’t really see how fundamentally the world around them is changing until long after the changes have occurred. So let’s start by declaring that the revolution has begun: Genomic research will dramatically transform both the practice of pharmacy and the way patients are treated with medications for many diseases.

The sequencing of the human genome was a huge scientific breakthrough, and it’s spawning additional breakthroughs as genetic testing labs spring up and the cost of testing individual patients for their ability to metabolize a particular drug drops to affordable levels for health plan payers.

It’s often the case that those in the midst of revolutionary times don’t really see how fundamentally the world around them is changing until long after the changes have occurred. So let’s start by declaring that the revolution has begun: Genomic research will dramatically transform both the practice of pharmacy and the way patients are treated with medications for many diseases.

April 13, 2012

Drug companies invested nearly $50 billion in research and development in 2011, according to a new report by a drug industry trade group.

WASHINGTON — Drug companies invested nearly $50 billion in research and development in 2011, according to a new report by a drug industry trade group.

May 11, 2011

Pharmacy benefit manager Medco’s research arm is teaming up with personalized medicine and pharmacogenetics company AssureRx Health in a pilot program to evaluate adherence and medical care utilization among patients taking antidepressants and antipsychotics.

FRANKLIN LAKES, N.J. — Pharmacy benefit manager Medco’s research arm is teaming up with personalized medicine and pharmacogenetics company AssureRx Health in a pilot program to evaluate adherence and medical care utilization among patients taking antidepressants and antipsychotics.

October 20, 2010

The Food and Drug Administration has approved a biotech drug for treating cancer of the...

SOUTH SAN FRANCISCO, Calif. The Food and Drug Administration has approved a biotech drug for treating cancer of the stomach and esophageal junction.

 

Genentech, a subsidiary of Swiss drug maker Roche, announced Wednesday the approval of Herceptin (trastuzumab) as a treatment for cancer of the stomach that includes the HER2 gene and has spread to other parts of the body, when combined with chemotherapy. The drug has long since had approval as a treatment for HER2-positive breast cancer.

 

 

August 29, 2010

The dizzying array of technical terminology that emerged from Venebio president and CEO Lenn Murrelle’s...

December 22, 2009

If there was any doubt as to the value CVS Caremark places on personalized medicine,...

NEW YORK If there was any doubt as to the value CVS Caremark places on personalized medicine, that doubt no longer should exist.

Clearly, the company believes that one area its PBM can create real value for payers is within pharmacogenomics or personalized medicine. Not only has CVS Caremark tapped Per Lofberg, co-founder of genetic benefit management company Generation Health, to serve as the PBM president, but it also has upped its stake in Generation Health.